iBio to Report Fiscal Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update on Monday, September 27, 2021

Rhea-AI Summary

iBio, Inc. (NYSEA:IBIO) is set to report its fiscal fourth quarter and full year 2021 financial results on September 27, 2021, before market open. Management will host a webcast and conference call at 8:30 a.m. ET to discuss the results and provide a corporate update. iBio is renowned for its FastPharming Manufacturing System®, focusing on sustainable, plant-based biopharmaceuticals. The company develops proprietary treatments for cancers, fibrotic, and infectious diseases while offering FastPharming Contract Development and Manufacturing Services.

Positive

• Planned financial results announcement may indicate progress.
• Company's focus on sustainable biopharmaceuticals aligns with industry trends.

Negative

• None.

BRYAN, Texas, Sept. 20, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System^®, announced today that it will report its fiscal fourth quarter and full year 2021 financial results before market open on Monday, September 27, 2021. iBio management will host a webcast and conference call at 8:30 a.m. Eastern Time to discuss the results and provide a corporate update.

The live and archived webcast may be accessed on the Company’s website at www.ibioinc.com under “News and Events” in the Investors section. The live call can be accessed by dialing (833) 672-0651 (domestic) or (929) 517-0227 (international) and referencing conference code: 7159935.

About iBio, Inc.

iBio is a developer of next-generation biopharmaceuticals and a pioneer in sustainable, plant-based biologics manufacturing. Its FastPharming System^® combines vertical farming, automated hydroponics, and novel glycosylation technologies to rapidly deliver high-quality monoclonal antibodies, vaccines, bioinks and other proteins. iBio is developing proprietary biopharmaceuticals for the treatment of cancers, as well as fibrotic and infectious diseases. The Company’s subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services along with Glycaneering Development Services™ for advanced recombinant protein design. For more information, visit www.ibioinc.com.

Contact:

Stephen Kilmer
iBio, Inc.
Investor Relations
(646) 274-3580
skilmer@ibioinc.com

FAQ

When will iBio report its fiscal fourth quarter and full year 2021 financial results?

iBio will report its fiscal fourth quarter and full year 2021 financial results on September 27, 2021.

What time is the iBio conference call scheduled?

The iBio conference call is scheduled for 8:30 a.m. Eastern Time on September 27, 2021.

How can I access the iBio financial results webcast?

The webcast can be accessed on iBio's website under the 'News and Events' section in the Investors area.

What is the focus of iBio's biopharmaceutical development?

iBio focuses on next-generation biopharmaceuticals, particularly treatments for cancers, fibrotic, and infectious diseases.